Cytosorbents (CTSO)
(Delayed Data from NSDQ)
$1.30 USD
-0.09 (-6.47%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $1.32 +0.02 (1.54%) 5:08 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
CTSO 1.30 -0.09(-6.47%)
Will CTSO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CTSO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CTSO
CytoSorbents (CTSO) Reports Q3 Loss, Misses Revenue Estimates
CytoSorbents (CTSO) Reports Q2 Loss, Lags Revenue Estimates
CTSO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
Other News for CTSO
Executive reshuffles: The ODP, GrafTech International and ICON Companies in focus
CytoSorbents Announces CFO Transition and New Financial Leadership
CytoSorbents Stability and Growth Prospects Maintain ‘Hold’ Rating Amid FDA Submission Uncertainty
Cytosorbents Corporation (CTSO) Q2 2024 Earnings Call Transcript
Here's the major earnings after the close today